小児気管支喘息に於けるテオフィリン投与法に関する研究-2-持続性テオフィリン・ノスカピン製剤(テオナ,テオナ-P)投与における血清テオフィリン濃度と臨床効果について

概要

論文の詳細を見る
The clinical effects of sustained-release theophylline (Theona or Theona-P) and its serum theophylline level were studied in 21 asthmatic children. In the first group consisting of 11 cases receiving a single dose of Theona or Theona-P, 8.6±1.4mg/kg, the average serum theophylline level was measured across several time intervals ; 2.1±1.9μg/ml after 1 hr, 4.0±2.3μg/ml after 2 hrs, 5.5±1.9 μg/ml after 4 hrs, 7.5±2.5μg/ml after 8 hrs, 6.3±1.3μg/ml after 12 hrs, 3.0±2.5μg/ml after 12 hrs. The mean value of the maximal serum theophylline level was 8.0±2.4μg/ml 8 hrs following administration in 72% of the cases and 12 hrs after administration in 28% of the cases. In the second group consisting of 10 asthmatic children receiving average doses of 8.7±2.1 mg/kg/dose every 12 hrs, clinical efficacy and serum theophylline levels were measured. In our study, the average serum theophylline level was maintained with a slight variance of below or above 10μg/ml throughout the day. The mean difference between maximum and minimum serum theophylline levels was 4.3±2.3μg/ml with a 12-hr dosage regimen. In the second group, the frequency of asthmatic attack was significantly decreased and, also, pulmonary function test (PFR) showed remarkable improvement. Eighty percent of the clinically moderate and severe cases experienced therapeutic benefit after a 12-hr administration of sustained-released theophylline preparation.
学校法人昭和大学・昭和医学会の論文

小児気管支喘息に於けるテオフィリン投与法に関する研究-2-持続性テオフィリン・ノスカピン製剤(テオナ,テオナ-P)投与における血清テオフィリン濃度と臨床効果について

スポンサーリンク

概要

著者

関連論文

スポンサーリンク